The Impact of FDA Draft Guidance for Oncology Patient-Reported Outcomes Date Published: Sep 10, 2021 Whitepaper Signant’s in-house experts discuss the key takeaways from recent FDA draft guidance on the use of patient-reported outcomes (PROs) in oncology clinical trials, including the recommended measures and frequency in administration. Readers will also learn the core domains that the agency values the most when reviewing oncology PROM data. Download Now Share: LinkedInTweet Recommended Resources Video Oncology Complete Solution Overview Oncology research today is more multifaceted and nuanced than ever. Sponsors and CROs need flexible, appropriate technology solutions and oncology-specific scientific... Watch Now Decentralized Clinical Trial Solutions Download Now Brochure Video Four Pillars for eCOA Success Whether you are conducting early-phase, local research or pivotal multinational trials, an effective electronic clinical outcome assessment (eCOA) solution helps... Watch Now